Search Results - "Legat, F.J."

Chronic nodular prurigo: clinical profile and burden. A European cross‐sectional study by Pereira, M.P., Hoffmann, V., Weisshaar, E., Wallengren, J., Halvorsen, J.A., Garcovich, S., Misery, L., Brenaut, E., Savk, E., Potekaev, N., Lvov, A., Bobko, S., Szepietowski, J.C., Reich, A., Bozek, A., Legat, F.J., Metz, M., Streit, M., Serra‐Baldrich, E., Gonçalo, M., Storck, M., Greiwe, I., Nau, T., Steinke, S., Dugas, M., Ständer, S., Zeidler, C., Dalgard, F., Elberling, J., Forner, C., Leslie, T., Riepe, C., Schneider, G., Ständer, H.

“…Background Chronic nodular prurigo (CNPG) is a condition characterized by chronic itch, a prolonged scratching behaviour and the presence of pruriginous…”
Get full text

European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo by Pereira, M.P., Steinke, S., Zeidler, C., Forner, C., Riepe, C., Augustin, M., Bobko, S., Dalgard, F., Elberling, J., Garcovich, S., Gieler, U., Gonçalo, M., Halvorsen, J. A., Leslie, T.A., Metz, M., Reich, A., Şavk, E., Schneider, G., Serra‐Baldrich, E., Ständer, H.F., Streit, M., Wallengren, J., Weller, K., Wollenberg, A., Bruland, P., Soto‐Rey, I., Storck, M., Dugas, M., Weisshaar, E., Szepietowski, J.C., Legat, F.J., Ständer, S.

“…Background The term prurigo has been used for many decades in dermatology without clear definition, and currently used terminology of prurigo is inconsistent…”
Get full text

Cross‐European validation of the ItchyQoL in pruritic dermatoses by Zeidler, C., Steinke, S., Riepe, C., Bruland, P., Soto‐Rey, I., Storck, M., Garcovich, S., Blome, C., Bobko, S., Legat, F.J., Potekaev, N., Lvov, A., Misery, L., Weger, W., Reich, A., Şavk, E., Streit, M., Serra‐Baldrich, E., Szepietowski, J.C., Yosipovitch, G., Chen, S.C., Dugas, M., Ständer, S.

“…Background Chronic pruritus (CP) is a frequently occurring symptom in inflammatory dermatoses, causing a high burden and limitations to health‐related quality…”
Get full text

European EADV network on assessment of severity and burden of Pruritus (PruNet): first meeting on outcome tools by Ständer, S., Zeidler, C., Riepe, C., Steinke, S., Fritz, F., Bruland, P., Soto-Rey, I., Storck, M., Agner, T., Augustin, M., Blome, C., Dalgard, F., Evers, A.W.M., Garcovich, S., Gonçalo, M., Lambert, J., Legat, F.J., Leslie, T., Misery, L., Raap, U., Reich, A., Şavk, E., Streit, M., Serra-Baldrich, E., Szepietowski, J., Wallengren, J., Weisshaar, E., Dugas, M.

“…Background Chronic pruritus is a frequently occurring symptom of various dermatoses that causes a high burden and impaired quality of life. An effective anti…”
Get full text

Effects of the non-peptide B 2 receptor antagonist FR173657 in models of visceral and cutaneous inflammation by Griesbacher, T., Legat, F.J.

Get full text

Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances by Ständer, S., Yosipovitch, G., Lacour, J.‐P., Legat, F.J., Paul, C., Reich, A., Chaouche, K., Ahmad, F., Piketty, C.

“…Background Patients with prurigo nodularis (PN) have multiple itchy nodules, impaired quality of life and sleep deprivation. Prurigo nodularis patients have a…”
Get full text

Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open‐label extension phase by Weisshaar, E., Szepietowski, J.C., Bernhard, J.D., Hait, H., Legat, F.J., Nattkemper, L., Reich, A., Sadoghi, B., Sciascia, T.R., Zeidler, C., Yosipovitch, G., Ständer, S.

“…Background Treatment of prurigo nodularis (PN) is challenging and new treatment options are needed. Objective To evaluate the efficacy and safety of two oral…”
Get full text

071 Aprepitant, a NK1-antagonist, administered for 16 weeks reduced itch and supported resolution of skin lesions in a patient with chronic prurigo by Legat, F.J., Gruber-Wackernagel, A., Hofer, A., Waltner, K., Wolf, P.

Get full text

Daylight photodynamic therapy: where and when is it possible? by Legat, F.J., Wolf, P.

“…Linked Article: O'Mahoney et al. Br J Dermatol 2017; 176:1607–1616…”
Get full text

Pruritus Intensity Scales across Europe: a prospective validation study by Storck, M., Sandmann, S., Bruland, P., Pereira, M.P., Steinke, S., Riepe, C., Soto‐Rey, I., Garcovich, S., Augustin, M., Blome, C., Bobko, S., Legat, F.J., Potekaev, N., Lvov, A., Misery, L., Weger, W., Reich, A., Şavk, E., Streit, M., Serra‐Baldrich, E., Szepietowski, J.C., Dugas, M., Ständer, S., Zeidler, C.

“…Background Chronic pruritus (CP) is a subjective symptom, and it is necessary to assess its intensity with validated patient‐reported outcome tools in order to…”
Get full text

Google search trends for itch in Europe: a retrospective longitudinal study by Pereira, M.P., Ziehfreund, S., Rueth, M., Ewering, T., Legat, F.J., Lambert, J., Elberling, J., Misery, L., Brenaut, E., Papadavid, E., Garcovich, S., Evers, A.W.M., Halvorsen, J.A., Szepietowski, J.C., Reich, A., Gonçalo, M., Lvov, A., Bobko, S., Serra‐Baldrich, E., Wallengren, J., Savk, E., Leslie, T., Ständer, S., Zink, A.

“…Background Itch is a common symptom in the general population. Affected individuals often do not seek medical consultation and rely on Internet searches to…”
Get full text

591 PUVA induces a shift in systemic T-cell function and Treg activity in lesional skin of MF patients by Vieyra-Garcia, P.A., Fink-Puches, R., Porkert, S., Lang, R., Pöchlauer, S., Ratzinger, G., Tanew, A., Selhofer, S., Sator, P., Cerroni, L., Hofer, A., Gruber-Wackernagel, A., LEGAT, F.J., Wolf, P.

Get full text

Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry by Inzinger, M., Heschl, B., Weger, W., Hofer, A., Legat, F.J., Gruber-Wackernagel, A., Tilz, H., Salmhofer, W., Quehenberger, F., Wolf, P.

“…Summary Background  Few studies have directly compared the clinical efficacy of psoralen plus ultraviolet A (PUVA) vs. biologics in the treatment of psoriasis…”
Get full text

Google search trends for itch in Europe: a retrospective longitudinal study by Pereira, M.P, Ziehfreund, S, Rueth, M, Ewering, T, Legat, F.J, Lambert, J, Elberling, J, Misery, Laurent, Brenaut, E, Papadavid, E, Garcovich, S, Evers, Andrea W, Halvorsen, Jon Anders, Szepietowski, Jacek C, Reich, Adam, Goncalo, M, Lvov, Andrey, Bobko, S, Serra-Baldrich, E, Wallengren, J, Savk, E, Leslie, T, Ständer, Sonja, Zink, A

“…Background Itch is a common symptom in the general population. Affected individuals often do not seek medical consultation and rely on Internet searches to…”
Get full text

Position Statement: Linear prurigo is a subtype of chronic prurigo by Pereira, M.P., Zeidler, C., Nau, T., Bobko, S., Evers, A.W.M., Garcovich, S., Gonçalo, M., Halvorsen, J.A., Lambert, J., Legat, F.J., Leslie, T., Metz, M., Misery, L., Nordlind, K., Reich, A., Schneider, G., Ständer, H., Streit, M., Szepietowski, J.C., Wallengren, J., Weisshaar, E., Ständer, S., Augustin, M., Brenaut, E., Dalgard, F.J., Elberling, J., Gieler, U., Kupfer, J., Lvov, A., Mittal, A., Savk, E., Serra‐Baldrich, E., Steinke, S., Tschachler, E., Weller, K.

“…Background Chronic prurigo (CPG) is a distinct disease characterized by chronic pruritus, history and/or signs of prolonged scratching and multiple pruriginous…”
Get full text

Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial by Wolf, P., Weger, W., Legat, F.J., Posch-Fabian, T., Gruber-Wackernagel, A., Inzinger, M., Salmhofer, W., Hofer, A.

“…Summary Background  Treatment with the interleukin‐12/23 antibody ustekinumab produces a satisfactory response [i.e. 75% reduction in Psoriasis Area and…”
Get full text

Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept by Wolf, P., Hofer, A., Legat, F.J., Bretterklieber, A., Weger, W., Salmhofer, W., Kerl, H.

“…Summary Background  Some patients with plaque‐type psoriasis respond slowly to treatment with etanercept. In such cases combining etanercept with conventional…”
Get full text

Short- to intermediate-term follow-up in patients treated with the combination of 311-nm ultraviolet B phototherapy and biological agents by Inzinger, M., Legat, F.J., Hofer, A., Weger, W., Gruber-Wackernagel, A., Salmhofer, W., Wolf, P.

Get full text

Randomized double-blinded placebo-controlled intra-individual trial on topical treatment with a 1,25-dihydroxyvitamin D3 analogue in polymorphic light eruption: Vitamin D3 analogue in PLE by Gruber-Wackernagel, A., Bambach, I., Legat, F.J., Hofer, A., Byrne, S.N., Quehenberger, F., Wolf, P.

Get full text

Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment by Horn, M., Wolf, P., Wulf, H.C., Warloe, T., Fritsch, C., Rhodes, L.E., Kaufmann, R., De Rie, M., Legat, F.J., Stender, I.M., Solér, A.M., Wennberg, A-M., Wong, G.A.E., Larkö, O.

“…Summary Background  Conventional treatment of basal cell carcinoma (BCC) causes morbidity and/or disfigurement in some patients because of the location (e.g…”
Get full text